Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has shown success in B-cell non-Hodgkin lymphoma (NHL).
• Treatment failure due to CD19 antigen loss or down-regulation and on-target, off-tumor effects (e.g., B-cell aplasia) limit efficacy and application, especially in chronic lymphocytic leukemia (CLL).

Purpose of the Study:

• To review alternative CAR targets and multi-specific CAR strategies for improving CAR T-cell therapy in lymphoma.
• To explore novel CAR targets and multi-antigen targeting approaches for various lymphoma types, including Hodgkin lymphoma and T-cell lymphoma.

Main Methods:

• Literature review of studied CAR targets for lymphoma.
• Analysis of multi-specific CAR designs targeting two or more antigens.
• Examination of cell surface antigens investigated for CAR-based therapies in lymphoma.

Main Results:

• CD19-CAR T-cell therapy is effective but limited by antigen escape and toxicity.
• Alternative CAR targets and multi-specific CARs are potential solutions for overcoming resistance and improving safety.
• Several novel antigens are under investigation for CAR targets in Hodgkin and T-cell lymphomas, with some showing promising clinical trial results.

Conclusions:

• Novel CAR targets and multi-antigen strategies are crucial for advancing CAR T-cell therapy in lymphoma.
• Developing tumor-agnostic CARs targeting antigens expressed across different lymphoma subtypes is a promising direction.
• Further research into alternative targets and combinatorial approaches is needed to enhance CAR T-cell therapy efficacy and broaden its application in hematologic malignancies.